Quantcast
Last updated on April 17, 2014 at 9:33 EDT

Latest Dana-Farber Cancer Institute Stories

2011-12-07 11:14:35

Study finds no evidence that androgen deprivation therapy causes heart attacks Hormone-blocking therapy for prostate cancer doesn't raise the risk of fatal heart attacks — as some recent studies had suggested — according to a new report from Dana-Farber/Brigham and Women's Cancer Center. For men with high-risk prostate tumors, a combination of local treatment and drugs that block male hormones that feed prostate tumors can significantly lengthen survival. In the past few...

2011-12-01 13:10:16

Study has implications for treatment of other immune-mediated disorders In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound. The phase I study, published in the Dec. 1 issue of the New England Journal of Medicine, involved allogeneic (donor)...

2011-12-01 10:47:45

Joslin study uncovers potential targets for treating disease Scientists at Joslin Diabetes Center in Boston have uncovered important molecular and genetic keys to the development of soft-tissue sarcomas in skeletal muscle, giving researchers and clinicians additional targets to stop the growth of these often deadly tumors. Published in the Proceedings of the National Academy of Sciences, the study identified two major molecular signaling pathways (the Ras and mTOR pathways) that are...

2011-11-24 11:18:04

2-drug combination may alleviate radiation sickness in people A combination of two drugs may alleviate radiation sickness in people who have been exposed to high levels of radiation, even when the therapy is given a day after the exposure occurred, according to a study led by scientists from Dana-Farber Cancer Institute and Children's Hospital Boston. Mouse studies of other potential therapies suggest they would be effective in humans only if administered within a few minutes or hours...

2011-11-14 08:00:00

Boston-based Internet stationery company, LookLoveSend, LLC is partnering with Dana-Farber Cancer Institute and the Jimmy Fund this holiday season to offer online access to high-quality printed, personalized holiday photo cards. The collection includes special Dana-Farber Cancer Institute photo cards, the proceeds from which will go directly to the Jimmy Fund. Shoppers may also choose to make a gift directly to the Jimmy Fund at checkout with any other holiday card purchases. Billerica, MA...

2011-11-01 15:00:00

2011 Grant Recipients and Scientific Merit Award Winner Announced NEW YORK, Nov. 1, 2011 /PRNewswire-USNewswire/ -- The Lung Cancer Research Foundation is announcing the 20 recipients of its 2011 research grants at its third annual Lung Cancer Symposium, tonight from 6-8 p.m. at the Times Center in New York, in commemoration of November as Lung Cancer Awareness Month. The free, open to the public session will feature distinguished thought leaders on a diverse set of topics linked to...

2011-11-01 08:30:00

BETHESDA, Md., Nov. 1, 2011 /PRNewswire/ -- The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium announced today the launch of a two-year clinical study aiming to advance the acceptance of new biomarkers designed to detect drug-induced kidney injury in clinical trials. The study is being conducted in collaboration with the Predictive Safety Testing Consortium (PSTC), a public-private partnership founded by the Arizona-based non-profit Critical Path Institute...

2011-10-27 22:10:00

Finding rewrites old theory of why chemo works Challenging a half-century-old theory about why chemotherapy agents target cancer, scientists at Dana-Farber Cancer Institute have devised a test that can predict how effective the drugs will be by determining whether a patient's tumor cells are already "primed" for death. In a study published online by the journal Science on Oct. 27, the researchers report that cancer cells that are on the verge of self-destruction are more likely to...

2011-10-27 13:00:00

BOSTON and CAMBRIDGE, Mass., Oct. 27, 2011 /PRNewswire/ -- A potentially groundbreaking approach to predicting cancer patient response to certain treatments is described today in the electronic version of Science Magazine. The paper describing the technology, called BH3 profiling, is published by Dr. Anthony Letai and colleagues at Boston's Dana Farber Cancer Institute. The technology assesses the ability of a key part of the cancer cell to respond to chemotherapies. This understanding...

2011-10-19 07:30:00

Awards Granted to 20 Researchers in Basic Science, Clinical and Translational Research NEW YORK, Oct. 19, 2011 /PRNewswire-USNewswire/ -- Understanding the genomic structure of lung cancer cells and the mechanisms that trigger their growth is the basis of research underway by Adam Bass, MD, winner of the 2011 Scientific Merit Award who will be celebrated at The Lung Cancer Research Foundation's third annual Lung Cancer Symposium, on November 1st in New York. Dr. Bass is one of 20...